Biocon

Businesses5 key growth verticals with the aim to deliver sustainable long term value for patients, partners, healthcare systems across the globe.

3 businesses1. Custom research (Syngene)2. Clinical development (Clinigene)3. Biopharmaceuticals (Biocon)

(the Holding Company)

Bangalore Subsidiary Bangalore Subsidiary

Bangalore Subsidiary

Switzerland Subsidiary

Malaysia Subsidiary Abu DhabiJoint venture company

Subsidiary Companies1. Syngene International Limited is a custom research organization

offering synthetic chemistry and molecular biology services for early stage drug discovery and development.

2. Biocon Pharma Limited (BPL) began as a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.

3. Biocon Research Limited (BRL) is a wholly owned subsidiary set up to undertake discovery and development research work in biologics, antibody molecules and proteins.

Subsidiary Companies4. NeoBiocon FZ LLC is a research and marketing pharmaceutical

company based in Abu Dhabi.5. Biocon SA is a wholly owned subsidiary in Switzerland primarily

engaged in the development and commercialization of biopharmaceuticals across the globe. Clinical Development of Insulin is currently ongoing in the European region.

6. Biocon SDN. BHD. is a wholly owned subsidiary in Malaysia to set up a state of the art manufacturing facility at BioXcell a biotechnology park promoted by the Government of Malaysia.

VisionTo enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe

MissionTo be an integrated biotechnology enterprise of global distinction.

Essential to this mission is excellence in:- Intellectual asset creation through discovery, research and development - State-of-the-art manufacturing capabilities- Internationally benchmarked quality and regulatory systems- New medical insight through disease specific clinical research- Customer relationship through outstanding products and services- Human resource development through training , mentoring and empowering- Management of research and business partnerships

ValuesIntegrity and Ethical Behaviour Performance driven work culture Value Creation through Innovation & Differentiation Quality through Compliance & Best Practices Collaboration, Team Work & Mutual Respect

Strategic Alliance• BIOCON – BRISTOL-MYERS SQUIBB: 2012

Biocon entered into an option agreement with Bristol-Myers Squibb for Biocon's IN-105, an oral insulin drug candidate

• Biocon to continue development of IN-105• Bristol-Myers Squibb will have an exclusive option to further develop and

commercialize IN-105

HistoryNovember 29, 1978

Biocon’s Founding Day

1979

Biocon is the first Indian company to manufacture and export enzymes to USA and

Europe

1989

Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its

subsidiary, Quest International

Biocon is the first Indian biotech company to receive US funding for proprietary

technologies

1993

Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV,

Germany

2000

Biocon commissions its first fully automated submerged fermentation plant

to produce specialty pharmaceuticals

Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to

pursue clinical research and development

2001

Biocon becomes the first Indian company to be approved by US FDA for the

manufacture of lovastatin, a cholesterol-lowering molecule

Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and

world-wide patent

2003

Biocon is the first company worldwide to develop human insulin on a Pichia

expression system

2004

Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only

the second Indian company to cross the $1 billion mark on the first day of listing.

2006

Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park

Biosimilars - therapy areas - cancer, diabetes and rheumatoid arthritis Key products of Biosimilars portfolio are Recombinant Human Insulin (rh-Insulin), Insulin Analogs and Monoclonal Antibodies (MAbs)

Branded Formulations – • Present in the chronic disease segment in India. • 5 therapeutic segments: Metabolics, Oncotherapeutics, Nephrology,

Comprehensive Care and ImmunotherapeuticsSmall Molecules – APIs Generic Formulations